Takeda hosts regional event to advance hereditary angioedema care in the Middle East
Dubai, UAE- December 2024- Global biopharmaceutical company Takeda recently hosted the event…
Takeda hosted inflammatory bowel disease “IBD Aware” forum in Riyadh
Riyadh, The Kingdom of Saudi Arabia, November 28, 2024: Global biopharmaceutical company…
DoH and Takeda Pharmaceuticals Ink Strategic Partnership
June 2024- The Department of Health – Abu Dhabi (DoH) signed a…
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 in cTTP
May 31, 2024- Takeda announced that the European Medicines Agency’s (EMA) Committee…
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab)
Osaka, Japan- April 2024- Takeda announced that the U.S. Food and Drug…
Takeda’s Global Initiative Brings IBD Challenges to the Forefront in the UAE
Dubai, UAE- March 2024- Takeda, the patient-centric biopharmaceutical company, brought its global…